Press

/Press

UbiVac CEO to Address FDA/AACR Workshop on Oncology Dosing and Participate in Congressional Briefing

July 16, 2017 Washington D.C. - UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will speak on July 20 at a workshop in the Capitol organized by the US Food & Drug

UbiVac CEO to Address FDA/AACR Workshop on Oncology Dosing and Participate in Congressional Briefing 2017-07-30T13:34:43+00:00

UbiVac Announces Positive Results of Phase II Adjuvant Clinical Trial

June 2, 2017 Chicago, Il. — UbiVac, www.ubivac.com, announced the results of their randomized phase II adjuvant clinical trial in patients with definitively-treated Stage III non-small cell lung cancer (NSCLC). Their data document the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to expand T cell clones and correlates with induction of immunity against a spectrum of

UbiVac Announces Positive Results of Phase II Adjuvant Clinical Trial 2017-06-02T12:46:11+00:00

UbiVac CEO Addresses International Symposium on Immunotherapy

May 12, 2017 Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the International Symposium on Immunotherapy held 12-13 May at the Royal Society, London, England. During his remarks, Dr. Fox will

UbiVac CEO Addresses International Symposium on Immunotherapy 2017-06-02T13:11:54+00:00

UbiVac Releases New Lung Cancer Clinical Trial Data: DPV-001 Vaccine Induces Broad Immunity Against Lung Cancer

Vienna, Austria.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a vaccine that educates the immune system to recognize and destroy cancer, is releasing new data at the 17th World Conference on Lung Cancer (WCLC), a meeting of the International Association for the Study of Lung Cancer (IASLC) held December 4-7 in Vienna. Rachel Sanborn, M.D., principal

UbiVac Releases New Lung Cancer Clinical Trial Data: DPV-001 Vaccine Induces Broad Immunity Against Lung Cancer 2016-12-08T09:25:46+00:00

UbiVac founder to open major cancer conference in Hong Kong

Hong Kong, China.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company whose lead product educates the immune system to recognize and destroy cancer, announces that its co-founder and CEO, Bernard A. Fox, PhD, will address the 21st Annual Scientific Symposium of the Hong Kong Cancer Institute on November 19th in Hong Kong. Symposium participants include internationally recognized experts

UbiVac founder to open major cancer conference in Hong Kong 2016-11-20T10:19:13+00:00

Positive Immune Response Data for Patients Receiving DPV-001 Presented by UbiVac at Society for Immunotherapy of Cancer Meeting

Washington, D.C.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a vaccine that educates the immune system to recognize and destroy cancer, is presenting new data at the 31st Annual meeting of the Society for Immunotherapy of Cancer (SITC) November 9-13 in National Harbor, Maryland. UbiVac presentations are detailing results of its adjuvant clinical trial in non-small

Positive Immune Response Data for Patients Receiving DPV-001 Presented by UbiVac at Society for Immunotherapy of Cancer Meeting 2016-11-14T06:59:57+00:00

UbiVac CEO to address World Life Science Conference in Beijing

Beijing, China.-- UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will address the World Life Science Conference in Beijing and co-chair a session on November 2nd entitled Clinical Medicine: Immunotherapy and Biotherapy. Professor

UbiVac CEO to address World Life Science Conference in Beijing 2016-11-02T09:06:53+00:00

Portland’s UbiVac To Brief International Immuno-Oncology Forum in Chicago

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2nd Annual 2016 Sachs Immuno-Oncology BD&L and Investment Forum on June 3 in Chicago. During his remarks, Dr. Fox will detail UbiVac’s

Portland’s UbiVac To Brief International Immuno-Oncology Forum in Chicago 2016-09-26T16:46:59+00:00

Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer

Washington DC—A Portland, Ore. specialist in the area of immunotherapy and immuno-oncology has been awarded the prestigious Visionary/Legacy Award by the Society for Immunotherapy of Cancer (SITC) at its 30th Anniversary Award Ceremony here. Dr. Bernard A. Fox, PhD, President and Chief Executive Officer, UbiVac, www.ubivac.com, and Harder Family Chair for Cancer Research, at the

Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer 2016-06-24T08:22:58+00:00